Armistice Capital »

Replimune Group shares owned by Armistice Capital

Quarter-by-quarter ownership of Replimune Group (REPL) shares owned by Armistice Capital from 13F filings

Historical chart of Armistice Capital investment in Replimune Group

Tip: Access up to 7 years of quarterly data

All positions including Replimune Group held by Armistice Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Replimune Group by Armistice Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $2.9M 264k 11.07

More positions owned by Armistice Capital

State Str Spdr S&p 500 Etf T Tr Unit Put Option (SPY)
Ishares Tr Russell 2000 Etf Put Option (IWM)
Cytokinetics Com New (CYTK)
Agios Pharmaceuticals (AGIO)
Madrigal Pharmaceuticals (MDGL)
Ptc Therapeutics I (PTCT)
Supernus Pharmaceuticals (SUPN)
Travere Therapeutics (TVTX)
Immunovant (IMVT)
Incyte Corporation (INCY)
Neurocrine Biosciences (NBIX)
UnitedHealth (UNH)
Mineralys Therapeutics (MLYS)
Freshpet (FRPT)
Dyne Therapeutics (DYN)

View all positions for Armistice Capital

Top funds holding Replimune Group

Baker Bros. Advisors
BlackRock
T. Rowe Price Associates
Rtw Investments
Ridgeback Capital Investments
Goldman Sachs Group
Suvretta Capital Management
Boxer Capital Management
Caption Management
State Street Corporation
Vanguard Capital Management
Fcpm Iii Services B.v.
Jane Street
AQR Capital Management
Logos Global Management

View all funds holding Replimune Group